← Back to Screener
Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR)
Price$17.57
Favorite Metrics
Price vs S&P 500 (26W)13.20%
Price vs S&P 500 (4W)-0.17%
Market Capitalization$1.05B
P/E Ratio (Annual)435.22x
All Metrics
P/CF (Annual)22.67x
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)7.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.30%
Cash Flow / Share (Quarterly)$0.08
Price vs S&P 500 (YTD)1.18%
Gross Margin (TTM)87.91%
Net Profit Margin (TTM)0.76%
EPS (TTM)$0.01
10-Day Avg Trading Volume13.61M
EPS Excl Extra (TTM)$0.01
Revenue Growth (5Y)12.13%
EPS (Annual)$0.00
ROI (Annual)0.73%
Gross Margin (Annual)87.90%
Net Profit Margin (5Y Avg)1.43%
Cash / Share (Quarterly)$0.26
P/E Basic Excl Extra (TTM)435.22x
Revenue Growth QoQ (YoY)14.92%
EPS Growth (5Y)-41.47%
P/E Normalized (Annual)435.22x
ROA (Last FY)0.57%
Revenue Growth TTM (YoY)26.55%
EBITD / Share (TTM)$0.06
ROE (5Y Avg)1.16%
Operating Margin (TTM)6.87%
Cash Flow / Share (Annual)$0.08
P/B Ratio4.48x
P/B Ratio (Quarterly)4.14x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.22x
Net Interest Coverage (TTM)1.99x
ROA (TTM)0.63%
EPS Growth QoQ (YoY)80.95%
EV / EBITDA (TTM)32.67x
EPS Incl Extra (Annual)$0.00
Current Ratio (Annual)2.59x
Quick Ratio (Quarterly)2.03x
3-Month Avg Trading Volume13.81M
52-Week Price Return102.31%
EV / Free Cash Flow (Annual)22.44x
P/E Incl Extra (TTM)435.22x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.20
P/S Ratio (Annual)3.30x
Asset Turnover (Annual)0.75x
52-Week High$1.82
Operating Margin (5Y Avg)3.49%
EPS Excl Extra (Annual)$0.00
CapEx CAGR (5Y)-45.22%
Tangible BV CAGR (5Y)10.15%
26-Week Price Return21.95%
Quick Ratio (Annual)1.97x
13-Week Price Return-6.82%
Total Debt / Equity (Annual)0.42x
Current Ratio (Quarterly)2.59x
Enterprise Value$1,210.836
Revenue / Share Growth (5Y)10.13%
Asset Turnover (TTM)0.83x
Book Value / Share Growth (5Y)6.58%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.75x
Pretax Margin (Annual)3.42%
Cash / Share (Annual)$0.26
3-Month Return Std Dev52.67%
Gross Margin (5Y Avg)89.31%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-14.62%
EBITDA Interim CAGR (5Y)-34.72%
ROE (Last FY)1.03%
Net Interest Coverage (Annual)1.99x
EPS Basic Excl Extra (Annual)$0.00
P/FCF (TTM)22.97x
Receivables Turnover (TTM)6.87x
EV / Free Cash Flow (TTM)22.44x
Total Debt / Equity (Quarterly)0.42x
EPS Incl Extra (TTM)$0.01
Receivables Turnover (Annual)9.03x
ROI (TTM)0.77%
P/S Ratio (TTM)3.30x
Pretax Margin (5Y Avg)2.91%
Revenue / Share (Annual)$0.50
Tangible BV / Share (Annual)$0.21
Forward P/E86.36x
Free OCF CAGR (5Y)-4.61%
Price vs S&P 500 (52W)67.21%
P/E Ratio (TTM)435.22x
Year-to-Date Return4.42%
5-Day Price Return-2.01%
EPS Normalized (Annual)$0.00
ROA (5Y Avg)0.51%
Net Profit Margin (Annual)0.76%
Month-to-Date Return3.84%
Cash Flow / Share (TTM)$-0.01
EBITD / Share (Annual)$0.05
EPS Growth (3Y)-41.82%
Operating Margin (Annual)6.87%
LT Debt / Equity (Annual)0.33x
P/CF (TTM)22.67x
ROI (5Y Avg)0.53%
P/E Excl Extra (TTM)435.22x
LT Debt / Equity (Quarterly)0.33x
EPS Basic Excl Extra (TTM)$0.01
P/TBV (Quarterly)8.11x
P/B Ratio (Annual)4.14x
Inventory Turnover (TTM)0.75x
Pretax Margin (TTM)3.42%
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)-9.69%
Net Margin Growth (5Y)-46.77%
Beta0.80x
P/FCF (Annual)22.99x
Revenue / Share (TTM)$0.54
ROE (TTM)1.15%
52-Week Low$0.73
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.43
4.43
4.43
4.43
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PHARPharming Group N.V. ADS, each representing 10 ordinary shares | 3.30x | 26.55% | 87.91% | -41.47% | $17.57 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Pharming Group is a biopharmaceutical company focused on rare and life-threatening diseases with unmet medical needs. It markets RUCONEST for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, supported by a pipeline of biologic and small-molecule therapies in development.